Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer

PURPOSE: Mutations in the RET proto-oncogene and vascular endothelial growth factor receptor (VEGFR) activity are critical in the pathogenesis of medullary thyroid cancer (MTC). Sorafenib, a multikinase inhibitor targeting Ret and VEGFR, showed antitumor activity in preclinical studies of MTC. PATIE...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Lam, Elaine T., Ringel, Matthew D., Kloos, Richard T., Prior, Thomas W., Knopp, Michael V., Liang, Jiachao, Sammet, Steffen, Hall, Nathan C., Wakely, Paul E., Vasko, Vasyl V., Saji, Motoyasu, Snyder, Pamela J., Wei, Lai, Arbogast, Daria, Collamore, Minden, Wright, John J., Moley, Jeffrey F., Villalona-Calero, Miguel A., Shah, Manisha H.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Clinical Oncology 2010
Ämnen:
Original Reports
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2881718/
https://ncbi.nlm.nih.gov/pubmed/20368568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.0068
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk